| Hazard Information | Back Directory | [Uses]
Favezelimab (MK-4280) is a humanized anti-LAG-3 monoclonal antibody that blocks the interaction between LAG-3 and its ligand MHC class II. Favezelimab has the potential for colorectal cancer (CRC) research combined with the PD-L1 inhibitor Pembrolizumab.html" class="link-product" target="_blank">Pembrolizumab (HY-P9902)[1][2]. | [References]
[1] Carmen Belli, et al. Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies. Cancers (Basel). 2022 Sep 1;14(17):4278. DOI:10.3390/cancers14174278
[2] Gareth P. Gregory, et al. Abstract CT106: Anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: A Phase I/II study. ?Cancer Res (2019) 79 (13_Supplement): CT106. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|